| Targeting FGFR signaling in cancer M Touat, E Ileana, S Postel-Vinay, F André, JC Soria Clinical cancer research 21 (12), 2684-2694, 2015 | 509 | 2015 |
| Mechanisms and therapeutic implications of hypermutation in gliomas M Touat, YY Li, AN Boynton, LF Spurr, JB Iorgulescu, CL Bohrson, ... Nature 580 (7804), 517-523, 2020 | 445 | 2020 |
| Glioblastoma targeted therapy: updated approaches from recent biological insights M Touat, A Idbaih, M Sanson, KL Ligon Annals of Oncology 28 (7), 1457-1472, 2017 | 394 | 2017 |
| Immune checkpoint inhibitor-related myositis and myocarditis in patients with cancer M Touat, T Maisonobe, S Knauss, O Ben Hadj Salem, B Hervier, K Auré, ... Neurology 91 (10), e985-e994, 2018 | 301 | 2018 |
| BRAF inhibition in BRAFV600-mutant gliomas: results from the VE-BASKET study T Kaley, M Touat, V Subbiah, A Hollebecque, J Rodon, AC Lockhart, ... Journal of Clinical Oncology 36 (35), 3477, 2018 | 286 | 2018 |
| Detection, characterization, and inhibition of FGFR–TACC fusions in IDH wild-type glioma AL Di Stefano, A Fucci, V Frattini, M Labussiere, K Mokhtari, P Zoppoli, ... Clinical cancer research 21 (14), 3307-3317, 2015 | 249 | 2015 |
| IDH1 and IDH2 mutations as novel therapeutic targets: current perspectives J Mondesir, C Willekens, M Touat, S de Botton Journal of blood medicine, 171-180, 2016 | 239 | 2016 |
| Ivosidenib in isocitrate dehydrogenase 1–mutated advanced glioma IK Mellinghoff, BM Ellingson, M Touat, E Maher, I Macarena, M Holdhoff, ... Journal of clinical oncology 38 (29), 3398, 2020 | 195 | 2020 |
| Neurological toxicities associated with immune-checkpoint inhibitors M Touat, D Talmasov, D Ricard, D Psimaras Current opinion in neurology 30 (6), 659-668, 2017 | 187 | 2017 |
| Buparlisib in patients with recurrent glioblastoma harboring phosphatidylinositol 3-kinase pathway activation: an open-label, multicenter, multi-arm, phase II trial PY Wen, M Touat, BM Alexander, IK Mellinghoff, S Ramkissoon, ... Journal of clinical oncology 37 (9), 741, 2019 | 140 | 2019 |
| Clinical activity and safety of atezolizumab in patients with recurrent glioblastoma RV Lukas, J Rodon, K Becker, ET Wong, K Shih, M Touat, M Fassò, ... Journal of neuro-oncology 140, 317-328, 2018 | 134 | 2018 |
| Vorasidenib in IDH1-or IDH2-mutant low-grade glioma IK Mellinghoff, MJ Van Den Bent, DT Blumenthal, M Touat, KB Peters, ... New England Journal of Medicine 389 (7), 589-601, 2023 | 114 | 2023 |
| Emerging circulating biomarkers in glioblastoma: promises and challenges M Touat, A Duran-Peña, A Alentorn, L Lacroix, C Massard, A Idbaih Expert review of molecular diagnostics 15 (10), 1311-1323, 2015 | 81 | 2015 |
| Pembrolizumab-induced necrotic myositis in a patient with metastatic melanoma H Vallet, A Gaillet, N Weiss, C Vanhaecke, S Saheb, V Touitou, N Franck, ... Annals of Oncology 27 (7), 1352-1353, 2016 | 78 | 2016 |
| Successful treatment of multiple intracranial meningiomas with the antiprogesterone receptor agent mifepristone (RU486) M Touat, G Lombardi, P Farina, M Kalamarides, M Sanson Acta neurochirurgica 156, 1831-1835, 2014 | 65 | 2014 |
| FGFR1 actionable mutations, molecular specificities, and outcome of adult midline gliomas A Picca, G Berzero, F Bielle, M Touat, J Savatovsky, M Polivka, E Trisolini, ... Neurology 90 (23), e2086-e2094, 2018 | 59 | 2018 |
| PD1 pathway in immune-mediated myopathies: pathogenesis of dysfunctional T cells revisited S Knauss, C Preusse, Y Allenbach, S Leonard-Louis, M Touat, N Fischer, ... Neurology: Neuroimmunology & Neuroinflammation 6 (3), e558, 2019 | 51 | 2019 |
| Mismatch repair deficiency in high-grade meningioma: a rare but recurrent event associated with dramatic immune activation and clinical response to PD-1 blockade IF Dunn, Z Du, M Touat, MB Sisti, PY Wen, R Umeton, AM Dubuc, ... JCO precision oncology 2, 2018 | 48 | 2018 |
| Performance of next-generation sequencing for the detection of microsatellite instability in colorectal cancer with deficient DNA mismatch repair T Ratovomanana, R Cohen, M Svrcek, F Renaud, P Cervera, A Siret, ... Gastroenterology 161 (3), 814-826. e7, 2021 | 47 | 2021 |
| ACTR-46. AG-120, a first-in-class mutant IDH1 inhibitor in patients with recurrent or progressive IDH1 mutant glioma: updated results from the phase 1 non-enhancing glioma … IK Mellinghoff, M Touat, E Maher, M De La Fuente, TF Cloughesy, ... Neuro-Oncology 19 (suppl_6), vi10-vi11, 2017 | 47 | 2017 |
Marc SansonNeurologist, Sorbonne-UniversitéVerified email at aphp.fr
